Debora Barton - 13 Jun 2023 Form 4 Insider Report for TScan Therapeutics, Inc. (TCRX)

Reporting relationship: Chief Medical Officer
Issuer ticker: TCRX
Reported as of: 13 Jun 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 15 Jun 2023, 18:19:57 UTC
Prior SEC filing: 06 Feb 2023
Source filing: View source filing
Reporting owner signature: /s/ Debora Barton

Key filing fact

Debora Barton filed Form 4 for TScan Therapeutics, Inc. (TCRX) on 15 Jun 2023.

Key facts

This page summarizes Debora Barton's Form 4 filing for TScan Therapeutics, Inc. (TCRX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 15 Jun 2023, 18:19.

Change

Previous filing in this sequence was filed on 06 Feb 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TCRX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +430,000
Change %
Price: $0.000000
Shares after: 430,000
Date: 13 Jun 2023
Ownership: Direct
Underlying class: Voting Common Stock
Underlying amount: 430,000
Exercise price: $2.49
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

220,000 shares subject to this option shall vest and become exercisable with respect to 25% of the shares on the one-year anniversary of May 24, 2023, with the balance vesting thereafter in equal monthly installments over the next 36 months of continuous service to the Issuer. The remaining 210,000 shares subject to this option shall vest and become exercisable with respect to 25% of the shares on February 2, 2025, with the balance vesting thereafter in equal monthly installments over the next 36 months of continuous service to the Issuer, in each case subject to the Reporting Person's continued service at such time. This option was granted on May 24, 2023 subject to the approval of the Issuers' stockholders of an amendment to the TScan Therapeutics, Inc. 2021 Equity Incentive Plan, which was obtained on June 13, 2023.